Trial Profile
A Pilot Phase 2, Open-label, Non-randomized, Single Center Study to Explore Diagnostic Validity of [18F]Florbetaben Positron Emission Tomography for Detecting Amyloidosis in Multiple Myeloma Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Amyloidosis
- Focus Diagnostic use
- 16 Apr 2019 Status changed from recruiting to completed.
- 15 Nov 2018 New trial record